Curettage of Atypical cartilage tumor tied to overall increased fracture risk among males with larger lesions

Key findings from the study are:

· The study had 183 females and 114 males, with a median follow-up of 3.2 years.

· The mean diameter of the lesions was 4.5 cm.

· 259 Patients received augmentation with allograft bone, 11 with Polymethyl methacrylate (PMMA) and 27 did not receive augmentation.

· Overall fracture risk was 6%.

· For postoperative fractures, the male sex and lesion size larger than 3.8 cm were risk factors.

They said our study demonstrates that augmentation using allograft bone chips or PMMA after intralesional curettage of an ACT does not influence fracture risk.

A low number of fractures prohibited stratified or multivariable analysis to account for potential confounding; the window size, insufficient power and predefined follow-up of 90 days were some of the study's limitations.

Our study included a large group (297 patients) with a prolonged follow-up period. This study can function as a base for further research toward active surveillance, given the high postoperative fracture risk, especially for men with large tumor lesions.

This research serves as a foundation for future investigations into active surveillance, given the elevated risk of postoperative fractures, particularly in men with large tumor burdens, they said.

Reference:

Krebbekx, G.G.J., Fris, F.J., Schaap, G.R. et al. Fracture risk after intralesional curettage of atypical cartilaginous tumors. J Orthop Surg Res 18, 851 (2023). https://doi.org/10.1186/s13018-023-04215-4